Patents Examined by Catherine Mader
-
Patent number: 9868108Abstract: Sorbent comprising a solid support material, the surface of which comprises first residues comprising a binuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N, O, S, and second residues comprising a mononuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N, O, S.Type: GrantFiled: August 7, 2015Date of Patent: January 16, 2018Assignee: instrAction GmbHInventors: Klaus Gottschall, Markus Arendt, Andres Kirschfeld, Christian Meyer, Markus Weis, Martin Welter, Lothar Ziser
-
Patent number: 9828411Abstract: The present invention relates to a method for isolating caspofungin and to a novel crystalline form of caspofungin diacetate thus obtained.Type: GrantFiled: April 28, 2014Date of Patent: November 28, 2017Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.Inventors: Robertus Mattheus De Pater, Neeraj Tewari, Roop Singh Yadav
-
Patent number: 9828439Abstract: A hybrid vegetable protein is described, comprising a guest protein having the structure of prolamine and glutelin, and a host protein having the structure of globulin and albumin, obtained from vegetable grains, such as corn and soybean, respectively. Likewise, a method for obtaining said hybrid vegetable protein is described, which comprises the steps of extracting the guest and host proteins, carrying out an acidification thereof, and further applying a magnetic field to provoke their attachment, and finally adding an alkali to the attached proteins to obtain a hybrid vegetable protein at its isoelectric point. The protein thus produced has a value higher than 0.97 according to the PDCAAS rating.Type: GrantFiled: September 30, 2015Date of Patent: November 28, 2017Assignee: INDUSTRIAS NUTRIGRAINS, S.A., DE C.V.Inventor: José De La Torre-Montemayor
-
Patent number: 9822146Abstract: The present invention relates to a liquid (or solution)-phase manufacturing process for preparing the decapeptide Degarelix, its protected precursor, and other useful intermediates. The invention further relates to polypeptides useful in the solution-phase manufacturing process and to the purification of Degarelix itself. Degarelix can be obtained by subjecting a Degarelix precursor according to formula II: (P1)AA1-AA2-AA3-AA4(P4)-AA5-AA6(P6)-AA7-AA8(P8)-AA9-AA10-NH2 (II) or a salt or solvate thereof, to a treatment with a cleaving agent in an organic solvent, wherein P1 is an amino protecting groups; preferably acetyl; P4 is hydrogen or a hydroxyl protecting group, preferably a hydroxyl protecting group; P6 is hydrogen or an amino protecting groups; preferably an amino protecting groups; and P8 is an amino protecting group.Type: GrantFiled: June 23, 2015Date of Patent: November 21, 2017Assignee: Ferring B.V.Inventors: Jon Holbech Rasmusse, Jens Fornsgaard, Stefan Hansen, Palle Hedengran Rasmussen, Wolfgang Oliver Wachs
-
Patent number: 9821248Abstract: A method for obtaining a liquid from a porous solid phase is described. The method comprises forming a liquid seal at a first end of a porous solid phase to which a liquid is bound, wherein liquid of the liquid seal is immiscible with the liquid bound to the solid phase, and applying a pressure differential across the porous solid phase to cause the immiscible liquid to move through the porous solid phase towards a second end of the porous solid phase, thereby displacing the liquid bound to the porous solid phase towards the second end and releasing this liquid from the second end. Recovery of liquid from the solid phase using such methods is increased compared with corresponding methods in which no liquid seal is formed. In preferred embodiments, the liquid used to form the liquid seal is a mineral oil. The methods have particular application in nucleic acid extractions which utilize capture of nucleic acid to a solid phase. Kits and apparatus for performing the methods are also described.Type: GrantFiled: March 15, 2013Date of Patent: November 21, 2017Assignee: Cambridge Enterprise LimitedInventor: Yii Leng Chua
-
Patent number: 9814785Abstract: The invention provides a method for the prophylaxis or treatment of hepatitis C in a mammal with a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes; the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer; and the peptide is bound to the surface of the liposome. The invention also provides a cytotoxic T lymphocyte activator containing the peptide-bound liposome, as well as a hepatitis C virus vaccine.Type: GrantFiled: August 20, 2015Date of Patent: November 14, 2017Assignees: Saitama Medical University, Japan as represented by the Director-General of National Institute of Infectious Diseases, NOF CorporationInventors: Toshitaka Akatsuka, Tetsuya Uchida, Maiko Taneichi, Ai Mikuma, Shoichi Yokoyama
-
Patent number: 9796761Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.Type: GrantFiled: July 12, 2010Date of Patent: October 24, 2017Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, GLYCOBIOMARKER LEADING INNOVATION CO., LTD.Inventors: Hisashi Narimatsu, Jun Hirabayashi, Yuzuru Ikehara, Takashi Angata, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Toshihide Shikanai, Maki Sogabe, Akira Togayachi, Makoto Ochou, Yasuhito Tanaka, Masashi Mizokami
-
Patent number: 9796758Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.Type: GrantFiled: March 18, 2013Date of Patent: October 24, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITE LILLE 2 DROIT ET SANTEInventors: Oleg Melnyk, Laurent Raibaut, Nathalie Ollivier
-
Patent number: 9782455Abstract: The present invention relates to a method of preparing a peptide comprising the amino acid sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO:1). In particular, the method comprises the steps of providing a first peptide fragment having a first protection group, which peptide fragment is conjugated to a support; providing a second peptide fragment having a second protection group; removing the first protection group from the first peptide fragment; and coupling the second peptide fragment to the N-terminally deprotected, support-conjugated first peptide fragment. The present invention further relates to a method of preparing a pharmaceutical composition containing said peptide.Type: GrantFiled: August 30, 2011Date of Patent: October 10, 2017Assignee: NPS PHARMACEUTICALS, INC.Inventor: Don Wellings
-
Patent number: 9783571Abstract: The disclosure provides a capture system and methods for isolating cysteine-containing peptides from biological fluid and proteolytic mixtures. The disclosure also provides compounds of formulae (II), (III), and (IV), useful in methods of the invention.Type: GrantFiled: April 5, 2012Date of Patent: October 10, 2017Inventor: Warham Lance Martin
-
Patent number: 9770490Abstract: A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders.Type: GrantFiled: June 29, 2015Date of Patent: September 26, 2017Assignee: Billion King International Ltd.Inventors: Bing Lou Wong, Sui Yi Kwok
-
Patent number: 9770506Abstract: The invention is directed to a compound according to the formula [1] wherein R1 and R2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or O and R is —OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.Type: GrantFiled: March 7, 2016Date of Patent: September 26, 2017Assignee: ISA Pharmaceuticals, B.V.Inventors: Ferdinand Antonius Ossendorp, Cornelis Johannes Maria Melief, Selina Khan, Dmitri Viktorovitsj Filippov, Gijsbert Arie Van der Marel
-
Patent number: 9763889Abstract: A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders.Type: GrantFiled: February 4, 2016Date of Patent: September 19, 2017Assignee: Billion King International Ltd.Inventors: Bing Lou Wong, Sui Yi Kwok
-
Patent number: 9759720Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.Type: GrantFiled: September 23, 2011Date of Patent: September 12, 2017Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 9758542Abstract: A coating of a random copolymer of acrylamide and a second monomer, e.g. glycidoxylmethacrylate, for a silica surface is described. The coating is applied to chromatographic support structures having silica based surfaces. The coating is functionalized to produce protein chromatography matrices that are particularly useful for extracting trace amounts of biomarker molecules from biological samples.Type: GrantFiled: November 1, 2012Date of Patent: September 12, 2017Assignee: Purdue Research FoundationInventors: Mary J. Wirth, Yimin Hua, Zhaorui Zhang
-
Patent number: 9745340Abstract: The disclosure provides a method of separation of at least one ABD-containing molecule present in a liquid from other constituents in the liquid, comprising a step of affinity separation, in which step is used, as affinity ligand, an ABD binding polypeptide comprising an ABD binding motif BM, which motif consists of an amino acid sequence selected from (SEQ?ID?NO:?166) EX2X3X4AX6X7EIX10X11LPNLX16X17X18QX20X21AFIX25X26LX28D and amino acid sequences with at least 89% identity thereto.Type: GrantFiled: October 25, 2013Date of Patent: August 29, 2017Assignee: AFFIBODY ABInventors: Per Jonasson, Pär Eklund
-
Patent number: 9744246Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.Type: GrantFiled: June 6, 2012Date of Patent: August 29, 2017Assignee: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Patent number: 9739732Abstract: Provided is a stable isotope-labeled aliphatic amino acid enabling the assignment of the signal of an amino acid residue side chain by increasing to the maximum the observation sensitivity to an NMR signal of the same amino acid residue side chain, and allowing NOE (nuclear Overhauser effect) between protons in the amino acid residue to be observed. The stable isotope-labeled aliphatic amino acid is for constituting a protein and satisfies all of the following conditions (1) to (3): (1) two or more carbon atoms are labeled with 13C; (2) of two or more carbon atoms labeled with 13C, a carbon atom other than a carbon atom of a methyl group, which is capable of bonding to a hydrogen atom, has one 1H directly bonded thereto, while the carbon atom of the methyl group has at least one 1H directly bonded thereto; and (3) other carbon atoms adjacent to all the 13C are all 12C.Type: GrantFiled: February 18, 2013Date of Patent: August 22, 2017Assignee: Taiyo Nippon Sanso CorporationInventors: Masatsune Kainosho, Tsutomu Terauchi
-
Patent number: 9724622Abstract: There are only two ways to increase the amount of sample that can be purified by preparative reversed phase high performance liquid chromatography (Prep-RP-HPLC) in a single run: (1) The traditional approach is to use a bigger column (greater amount of stationary phase); and (2) Use displacement chromatography which uses the stationary phase more effectively. This invention describes a unique Prep-RP-HPLC technique that uses a C-18/C-8 derivatized silica coated with a hydrophobic quaternary ammonium salt or quaternary phosphonium salt to result in 7 to 12 fold increase in sample loading (of the crude mixture of organic compounds including synthetic crude peptides) in contrast to the conventional Prep-RP-HPLC technique. This increase in sample loading capacity and output is due to the additional surrogate stationary phase characteristic of the C-18/C8 bound quaternary salt. The quaternary surfactant is bound to the C-18/C-8 chains and silanols of the stationary phase.Type: GrantFiled: July 1, 2013Date of Patent: August 8, 2017Assignee: NEULAND HEALTH SCIENCES PRIVATE LIMITEDInventor: Mohammed Khalid Anwer
-
Patent number: 9724379Abstract: Therapeutic agents with improved fibrinogen binding properties are described. The agents are suitable for use as artificial platelets, or for formation of biogels. Methods and intermediates for producing the agents, cross-linking agents for use in the methods, and biogels formed from, or comprising the agents, are also described.Type: GrantFiled: February 1, 2012Date of Patent: August 8, 2017Assignee: Haemostatix LimitedInventor: Greg Walker